A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hypertension. Basic parameters: 18 years — 99 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates
Overview
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).
Primary outcome measures
- Change From Baseline to Week 4 in Mean Sitting SBP [Time frame: Baseline to Week 4]
Secondary outcome measures (3)
- Change From Baseline to Week 4 in Mean Sitting DBP [Time frame: Baseline to Week 4]
- Change From Baseline to Week 4 in Mean Sitting Pulse Pressure [Time frame: Baseline to Week 4]
- Proportion of Patients Achieving Target Office Blood Pressure at Weeks 4 and 12 [Time frame: Weeks 4 and 12]
Eligibility criteria
Inclusion criteria
- Adult male or female patients (≥18 years).
- Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association/American College of Cardiology \[AHA/ACC\] guidelines and/or the 2024 European Society of Cardiology \[ESC\] guidelines).
- Patients with documented office blood pressure ≥130/80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi.
- Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor/ARB/CCB) with a physician-directed requirement to transition to ARNi.
Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion.
- Patients willing to provide written informed consent to participate in the study.
Exclusion criteria
- Patients with malignant or severe hypertension (systolic blood pressure \[SBP\] ≥180 mmHg, diastolic blood pressure \[DBP\] ≥110 mmHg) at baseline.
- Patients with secondary causes of hypertension, as determined by the treating physician.
- Patients with a history of, or at risk of developing, angioedema.
- Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate \[eGFR\] <30 mL/min/1.73 m\^2).
- Pregnant or lactating women.
- Patients with serum potassium level ≥5.5 mmol/L at baseline.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07465666 · CLCZ696AAE01